Contact Us (781) 301-7474

Patient Advocacy

Learn more about these patient advocacy groups and our partnerships with them to increase disease awareness.

Sickle Cell Disease Association of America, Inc. and Hemanext® Inc. Form New Strategic Partnership

Sickle Cell Disease Association of America, Inc. (SCDAA) and Hemanext Inc., a privately held medical technology company dedicated to improving the quality, safety, efficacy and cost of red blood cell (RBC) transfusion therapy, are proud to announce a new partnership that will help SCDAA deliver on its mission and meet its goals. In 2020 Hemanext will collaborate with SCDAA on its educational programs, grassroots events and public-awareness campaigns.

Thalassaemia International Federation and Hemanext® Inc. Announce New Strategic Alliance

The Thalassaemia International Federation (TIF), a worldwide organization dedicated to ensuring equal access to quality healthcare for every patient with thalassaemia and other hemoglobin disorders across the world, and Hemanext Inc., a privately held medical technology company dedicated to improving patients’ quality of life by delivering a better red blood cell (RBC) replacement therapy, today announced a new strategic alliance on behalf of people living with thalassaemia.

CONNECT WITH HEMANEXT TODAY TO LEARN MORE!

We are happy to answer any questions about the company, our technology, or our research. Fill out the form below and we will connect with you!